1. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination;Boutros;Nat Rev Clin Oncol,2016
2. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque;Drobni;Circulation,2020
3. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials;Junqueira;Br Med J,2023
4. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology;Naidoo;J Immunother Cancer,2023
5. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks;Stegherr;Trials,2021